The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Rutgeerts et al., N Engl J Med 353(23):2462-2476 December 8, 2005.

Correction
PreviousPrevious
Volume 354:2200 May 18, 2006 Number 20
NextNext

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Rutgeerts, P.
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis . On page 2473 in Table 4, the percentage of patients in Active Ulcerative Colitis Trial (ACT) 2 receiving 10 mg of infliximab who had antibodies against double-stranded DNA should have read 6.0, rather than 60.0, as printed. We regret the error.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.